Why in the News?
Researchers at the Duke Human Vaccine Institute have successfully induced broadly neutralising antibodies (bNAbs) against HIV (human immunodeficiency virus) through vaccination for the first time.
About HIV/AIDS:
Causes:
Symptoms:
Vaccines Development:
|
How B cells and mRNA play distinct roles in the context of HIV infection?1. B cells (B lymphocytes):
2. mRNA (messenger RNA):
|
N332-GT5 and eOD-GT8: The New Vaccines in Making
- N332-GT5: This vaccine candidate targets a specific region on the surface of the HIV virus known as the N332 glycan site. By engaging B-cells that have the potential to produce bNAbs against this site, N332-GT5 aims to stimulate the immune system to generate a protective response against a wide range of HIV strains.
- eOD-GT8: Similarly, eOD-GT8 is designed to target another region on the HIV virus, known as the eOD protein. By leveraging nanoparticles as carriers, eOD-GT8 aims to enhance the immune system’s ability to recognize and neutralize HIV, ultimately leading to the production of bNAbs.
What are Broadly Neutralizing Antibodies (bNAbs)?
- In the 1990s, scientists discovered that some HIV-infected individuals produced bNAbs, which neutralize many viral strains.
- bNAbs target viral protein areas crucial for infectivity, making them less likely to change.
- Despite their effectiveness, bNAbs take years to develop, by which time HIV has often evolved to escape them.
Developing bNAb-Based Vaccines
- The goal is to make the immune system produce bNAbs quickly in response to a vaccine.
- Germline targeting involves three steps:
- Identify and engage B-cells capable of producing bNAbs.
- Use a booster to guide these cells to produce stronger bNAbs.
- Refine bNAbs to neutralize a wide range of HIV strains.
PYQ:[2013] Which of the following diseases can be transmitted from one person to another through tattooing? 1. Chikungunya 2. Hepatitis B 3. HIV-AIDS Select the correct answer using the codes given below. (a) 1 only (b) 2 and 3 only (c) 1 and 3 only (d) 1, 2 and 3 |




